- Home
- IBRX vs HTGC Comparison
IBRX vs HTGC Comparison
Compare IBRX & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- HTGC
- Stock Information
- Founded
- IBRX 2014
- HTGC 2003
- Country
- IBRX United States
- HTGC United States
- Employees
- IBRX N/A
- HTGC N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- HTGC Investment Managers
- Sector
- IBRX Health Care
- HTGC Finance
- Exchange
- IBRX Nasdaq
- HTGC Nasdaq
- Market Cap
- IBRX 2.4B
- HTGC 3.2B
- IPO Year
- IBRX N/A
- HTGC 2005
- Fundamental
- Price
- IBRX $2.08
- HTGC $17.49
- Analyst Decision
- IBRX Strong Buy
- HTGC Buy
- Analyst Count
- IBRX 5
- HTGC 8
- Target Price
- IBRX $11.35
- HTGC $20.81
- AVG Volume (30 Days)
- IBRX 8.8M
- HTGC 1.1M
- Earning Date
- IBRX 05-16-2025
- HTGC 05-01-2025
- Dividend Yield
- IBRX N/A
- HTGC 10.69%
- EPS Growth
- IBRX N/A
- HTGC N/A
- EPS
- IBRX N/A
- HTGC 1.33
- Revenue
- IBRX $14,745,000.00
- HTGC $491,549,000.00
- Revenue This Year
- IBRX $579.28
- HTGC $7.95
- Revenue Next Year
- IBRX $179.96
- HTGC $8.96
- P/E Ratio
- IBRX N/A
- HTGC $13.20
- Revenue Growth
- IBRX 2270.58
- HTGC 3.02
- 52 Week Low
- IBRX $1.83
- HTGC $15.65
- 52 Week High
- IBRX $9.16
- HTGC $22.04
- Technical
- Relative Strength Index (RSI)
- IBRX 36.89
- HTGC 44.90
- Support Level
- IBRX $1.83
- HTGC $17.27
- Resistance Level
- IBRX $2.17
- HTGC $18.13
- Average True Range (ATR)
- IBRX 0.18
- HTGC 0.31
- MACD
- IBRX -0.05
- HTGC 0.04
- Stochastic Oscillator
- IBRX 23.56
- HTGC 27.86
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.